-
Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum
Richter’s transformation (RT), a complication of chronic lymphocytic leukemia (CLL), poses significant diagnostic and therapeutic challenges. At the “2024 Nanjing Lymphoma Forum,” Professor Lei Fan from Jiangsu Provincial People’s Hospital delivered an academic report titled “Research Progress in Richter’s Transformation,” covering the latest advancements in its definition, characteristics, molecular mechanisms, and treatment progress. Hematology Frontier…
-
ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference
The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year’s ASCO conference, several…
-
Expert Commentary | Professor Lin Zhang: Efficacy and Safety of 90Y Resin Microsphere Radiation Segmentectomy for Hepatocellular Carcinoma
Traditionally, radiation dosage for yttrium-90 (90Y) resin microsphere radiation segmentectomy (RS) was determined using body surface area or partition models, which often resulted in lower prescription activities. Recent studies have used the Medical Internal Radiation Dosimetry (MIRD) formula to determine radiation doses, providing higher tumor absorption doses. A recent retrospective study published in Radiology by…
-
ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, Eastern Time. One study on OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy, garnered widespread attention. This research focuses on patients with immune checkpoint inhibitor (ICI)-resistant metastatic melanoma. Unlike traditional TIL therapy, OBX-115 has a…
-
ASCO 2024 | Advances in Uveal Melanoma Treatment
Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients’ vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO)…
-
Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients
Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients’ vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO)…
-
ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held in Chicago from May 31 to June 4. At this conference, Chinese researchers presented the first results of the Phase I study of SHR-A1912 in patients with B-cell non-Hodgkin lymphoma (B-NHL) on the international stage, including preliminary key data from the dose-escalation…
-
Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 31 to June 4. The ASCO Annual Meeting gathers oncology experts, doctors, and researchers from around the world to share the latest research findings, discuss cutting-edge diagnostic and therapeutic techniques, and advance the field of oncology. A study…
Connecting Medical Expertise through Media